Absci Corp

Absci has released early Phase 1 data for its lead antibody ABS-201 and secured a US$40 million investment and development support from Eli Lilly tied to the program. The company's share price has delivered a 77.55% 90-day return and a 160.66% year-to-date return, though the 30-day return is down 11.23%. Based on the most followed narrative, Absci's fair value of $13.78 sits above the last closing price of $9.41, framing the stock as 31.7% undervalued. However, on a price-to-book basis the stock looks expensive at 9.3x versus 2.5x for the US Biotechs industry and 9.1x for peers.

Absci Corporation shares climbed 11% after Eli Lilly made a $40 million investment and provided development support for ABS-201, Absci's prolactin receptor antibody. The investment extends Absci's cash runway into the second half of 2028 and comes alongside encouraging early Phase 1 data for ABS-201. Absci recently reported second-quarter 2026 results showing a net loss of $33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to $0.21. A Phase 2 endometriosis trial for ABS-201 is planned for late 2026, with Absci retaining rights to the program.

Absci Corporation announced positive interim Phase 1 data from its HEADLINE trial of ABS-201, an AI-designed antibody for pattern hair loss, and completed a $100 million underwritten offering that included a $40 million strategic investment from Eli Lilly & Company. The blinded, aggregate interim data suggest the study drug was well tolerated with a favorable safety profile, and the estimated half-life of at least 65 days supports a dosing interval of two or three injections over six months. Absci now expects its cash, cash equivalents, and marketable securities of $201.1 million as of June 30, 2026 to fund operations into the second half of 2028. The company anticipates reporting interim proof-of-concept data for pattern hair loss in the second half of 2026 and full proof-of-concept data in early 2027, and plans to initiate a Phase 2 trial for endometriosis in the fourth quarter of 2026. Net loss for the second quarter was $33.2 million, compared to $30.6 million in the prior-year period.

Absci Corporation priced a $100 million underwritten stock offering to advance its AI-designed antibody ABS-201, while also reporting positive interim Phase 1 results. The offering consists of 13.5 million shares at $7.41 per share, with proceeds earmarked for the ABS-201 program in androgenetic alopecia and endometriosis, as well as working capital. Interim data from 32 healthy adults showed ABS-201 was generally well tolerated, with no serious adverse events and a half-life of at least 65 days, potentially enabling dosing two or three times over six months. The company plans to continue evaluating ABS-201 in the multiple ascending dose portion of the HEADLINE study in androgenetic alopecia patients and expects to begin a Phase 2 trial in endometriosis later this year. As of March 31, 2026, Absci had $125.7 million in cash, cash equivalents, and marketable securities, which was expected to fund operations into the first half of 2028.

Absci shares surged 36% on Wednesday after the company reported positive interim data from the phase I portion of its ongoing phase I/IIa HEADLINE study evaluating ABS-201, an investigational PRLR antibody for androgenetic alopecia. The interim data from the single ascending dose portion, which enrolled 32 healthy participants, showed ABS-201 was well tolerated across all dose levels with no serious adverse events and an estimated half-life of at least 65 days, potentially supporting a dosing schedule of only two or three injections over six months. The study has now advanced into the subcutaneous multiple ascending dose portion, with interim proof-of-concept data expected in the second half of 2026 and full proof-of-concept results in early 2027. Absci also plans to initiate a phase II study of ABS-201 in endometriosis later this year. Year to date, Absci shares have skyrocketed 188.7% compared with the industry's 0.9% growth.

Six biotech stocks profiled by RTTNews have delivered stunning gains for patient investors, with Inhibrx Biosciences surging as much as 746% since its profile was published on July 8, 2025. Palvella Therapeutics rose up to 505% from its March 10, 2025 profile, driven by positive trial results and an FDA rolling review for its rare-disease therapy. MBX Biosciences gained up to 363% since June 18, 2025, following encouraging data from multiple clinical programs. Protagonist Therapeutics advanced as much as 204% from its January 6, 2025 profile after FDA approval of its psoriasis drug. Absci Corp. climbed up to 290% since September 12, 2025, on positive interim data for its AI-designed hair-loss treatment. Belite Bio increased up to 187% from its September 15, 2025 profile, supported by a completed rolling NDA submission for its retinal-disease therapy.

Absci shares surged 24% in premarket trading after the biotechnology company reported positive interim Phase 1 safety data for its hair-loss antibody treatment ABS-201, while FuelCell Energy jumped 16% on a strategic agreement to supply up to 380 megawatts of clean power for data centers. Cerebras Systems tumbled about 14% after forecasting 2026 adjusted gross margins of 38% to 41%, below the 47% margin reported in the first quarter, in its first earnings report since its IPO. FedEx fell 7.3% after issuing a fiscal 2027 earnings outlook that missed Wall Street expectations, despite reporting fourth-quarter earnings and revenue above estimates. Bilibili rose 2.4% after unveiling a new $300 million share repurchase program that will remain in place for 24 months.

Absci shares surged about 20% in premarket trading Monday after the biopharma announced $100 million in financing from Eli Lilly and several private equity firms. The company priced an underwritten offering of 13,495,277 shares at $7.41 per share. Private equity investors include Adage, BVF Partners, Columbia Threadneedle, Invus, and Redmile. Absci said it will use the proceeds to support ABS-201, its anti-PRLR antibody for androgenetic alopecia and endometriosis, as well as for working capital and general corporate purposes.

Absci Corporation, a clinical-stage biopharmaceutical company, is advancing its lead AI-designed antibody therapy ABS-201 into human clinical testing for androgenetic alopecia. The ongoing HEADLINE trial has generated encouraging early safety data, validating the company's generative AI platform for drug discovery. Absci's technology aims to accelerate development timelines and reduce costs compared to traditional methods, with additional pipeline opportunities in areas such as endometriosis. As of June 15th, shares traded at $7.27, and 23 hedge funds held the stock at the end of the first quarter, up from 16 in the prior quarter.